Prognostic factors for the course of functional status of patients with ALS: a systematic review

The progressive course of amyotrophic lateral sclerosis (ALS) results in an ever-changing spectrum of the care needs of patients with ALS. Knowledge of prognostic factors for the functional course of ALS may enhance clinical prediction and improve the timing of appropriate interventions. Our objective was to systematically review the evidence regarding prognostic factors for the rate of functional decline of patients with ALS, assessed with versions of the ALS Functional Rating Scale (ALSFRS). Two reviewers independently assessed the methodological quality of the thirteen included studies using the Quality in Prognosis Studies (QUIPS) tool. The overall quality of evidence for each prognostic factor was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, considering risk of bias, imprecision, inconsistency, indirectness, and publication bias. The quality of evidence for the prognostic value of age at onset, site of onset, time from symptom onset to diagnosis, and ALSFRS-Revised baseline score was low, mainly due to the limited data and inconsistency of results in the small number of studies included. The prognostic value of initial rate of disease progression, age at diagnosis, forced vital capacity, frontotemporal dementia, body mass index, and comorbidity remains unclear. We conclude that the current evidence on prognostic factors for functional decline in ALS is insufficient to allow the development of a prediction tool that can support clinical decisions. Given the limited data, future prognostic studies may need to focus on factors that have a predictive value for a decline in ALSFRS(-R) domain scores, preferably based on internationally collected and shared data.

[1]  A. Chiò,et al.  Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  A. L. La Spada,et al.  ALS motor phenotype heterogeneity, focality, and spread , 2009, Neurology.

[3]  M. Swash,et al.  Controversies and priorities in amyotrophic lateral sclerosis , 2013, The Lancet Neurology.

[4]  C. Lengeler,et al.  Language bias in randomised controlled trials published in English and German , 1997, The Lancet.

[5]  The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. , 1996, Archives of neurology.

[6]  D. Levy,et al.  Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients , 2013, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[7]  Robert H. Brown,et al.  Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[8]  Maurizio Fava,et al.  Amyotrophic lateral sclerosis disease progression model , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[9]  D. Moher,et al.  Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews , 1996, The Lancet.

[10]  Craig K. Enders,et al.  The influence of personality factors on disease progression and health‐related quality of life in people with ALS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[11]  O. Hardiman,et al.  Cognitive changes predict functional decline in ALS , 2013, Neurology.

[12]  B. Mohammadi,et al.  ALSFRS-R score and its ratio: A useful predictor for ALS-progression , 2008, Journal of the Neurological Sciences.

[13]  S. Paganoni,et al.  Uric acid levels predict survival in men with amyotrophic lateral sclerosis , 2012, Journal of Neurology.

[14]  Lucette Lacomblez,et al.  Progression in ALS is not linear but is curvilinear , 2010, Journal of Neurology.

[15]  Matthew C Kiernan,et al.  Biomarkers in amyotrophic lateral sclerosis , 2009, The Lancet Neurology.

[16]  M. Swash,et al.  Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis? , 2006, Archives of neurology.

[17]  J. Broach,et al.  Genetic heterogeneity of amyotrophic lateral sclerosis: Implications for clinical practice and research , 2014, Muscle & nerve.

[18]  E. Steyerberg,et al.  Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research , 2013, PLoS medicine.

[19]  A. Chiò,et al.  Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  J. Cedarbaum,et al.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.

[21]  G. Logroscino,et al.  Natural history of upper motor neuron-dominant ALS , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[22]  E. Beghi,et al.  Prognostic factors in ALS: A critical review , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[23]  M. Kiernan,et al.  Development of a model to guide decision making in amyotrophic lateral sclerosis multidisciplinary care , 2015, Health expectations : an international journal of public participation in health care and health policy.

[24]  S. Petri,et al.  Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis , 2013, European journal of neurology.

[25]  G. Guyatt,et al.  GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. , 2011, Journal of clinical epidemiology.

[26]  O. Hardiman,et al.  Amyotrophic lateral sclerosis , 2011, The Lancet.

[27]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[28]  A. Forbes,et al.  Clinical phenotypes and natural progression for motor neuron disease: Analysis from an Australian database , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[29]  Douglas G Altman,et al.  Systematic reviews of evaluations of prognostic variables , 2001, BMJ : British Medical Journal.

[30]  Howard Balshem,et al.  GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.

[31]  Robert H. Brown,et al.  Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS) , 2006, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[32]  M. Sabatelli,et al.  Uncovering amyotrophic lateral sclerosis phenotypes: Clinical features and long-term follow-up of upper motor neuron-dominant ALS , 2011, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[33]  Alan Tennant,et al.  The use of raw scores from ordinal scales: time to end malpractice? , 2012, Journal of rehabilitation medicine.

[34]  Daniel Stahl,et al.  Latent Cluster Analysis of ALS Phenotypes Identifies Prognostically Differing Groups , 2009, PloS one.

[35]  K. Kaiboriboon,et al.  A role for functional classification in the early identification of prognostic factors in ALS , 2007, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[36]  C. Bombardier,et al.  Assessing Bias in Studies of Prognostic Factors , 2013, Annals of Internal Medicine.

[37]  L. Goldstein,et al.  Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment , 2013, The Lancet Neurology.

[38]  F. Khan,et al.  Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease. , 2009, The Cochrane database of systematic reviews.

[39]  L. Ouchchane,et al.  Rates of progression of weight and forced vital capacity as relevant measurement to adapt Amyotrophic Lateral Sclerosis management for patient Result of a French multicentre cohort survey , 2013, Journal of the Neurological Sciences.

[40]  A. Voustianiouk,et al.  ALSFRS and appel ALS scores: Discordance with disease progression , 2008, Muscle & nerve.

[41]  A. Al-Chalabi,et al.  A proposed staging system for amyotrophic lateral sclerosis , 2012, Brain : a journal of neurology.

[42]  Jill Hayden,et al.  Evaluation of the Quality of Prognosis Studies in Systematic Reviews , 2006, Annals of Internal Medicine.